Wagner Macula & Retina Center Adopts Novel Technology to Protect Community Eye Health During the COVID-19 Pandemic

Partnering with Eyenuk to Identify At-Risk Patients Using Telemedicine and AI

VIRGINIA BEACH, Va.--(BUSINESS WIRE)-- Eyenuk, Inc. announced today that it has partnered with Wagner Macula & Retina Center (WMRC), a leading research and treatment center specializing in diabetic retinopathy, macular degeneration, eye tumors, and the diagnosis and management of complex medical and surgical eye disease, to deliver Eyenuk’s state-of-the-art telemedicine and artificial intelligence (AI) enabled ophthalmology solutions in the Hampton Roads Region of Virginia and North Carolina, home to more than 1.8 million people.

Maintaining healthy sight for the at-risk population does not need to be compromised as communities around the world maintain social distancing to fight the spread of COVID-19. With nine full-service clinics, Wagner Macula & Retina Center is taking the lead in the region to expand its telemedicine services to provide high quality eye screening conducted remotely, while keeping its clinics open for timely treatment of needed patients even during the COVID-19 pandemic.

Through partnership with Eyenuk, Inc., a Los Angeles based global artificial intelligence (AI) medical technology and services company, WMRC has deployed Eyenuk’s EyeScreen™ Human+AI Diagnostic Service to screen patient risks for diabetic retinopathy (DR) and other eye conditions. The EyeScreen Service is a novel AI-enabled telemedicine approach to disease detection that utilizes independent, unbiased interpretation by a human expert and a validated AI system. After the retinal images are independently assessed by both the AI disease detection system and specialist human graders separately, an ICD-10 compliant report is sent to the physician. In the event that the AI and human graders disagree, the images are adjudicated by another highly experienced human expert.

“Silently-progressing, blinding eye diseases such as diabetic retinopathy do not stop during the COVID-19 pandemic,” commented Alan L. Wagner, M.D., F.A.C.S., F.I.C.S., A.M.E., an internationally renowned ophthalmologist specializing in vitreoretinal surgery and research. “Eyenuk’s novel telemedicine and AI technologies enable WMRC to screen at-risk patients remotely and accurately, bringing care to more of our at-risk community, and free up our physicians’ time to focus on clinic patients and those requiring surgery, even during the pandemic.”

About Wagner Macula & Retina Center (WMRC)

Wagner Macula & Retina Center specializes in diabetic retinopathy, macular degeneration, eye tumors, and the diagnosis and management of complex medical and surgical eye disease. They are the preferred referral for National Retina Centers of Excellence and the preeminent provider of adult and pediatric macula and retina treatments located in the Hampton Roads region of Virginia & North Carolina. Their state-of-the-art facilities offer the latest technology and treatments to save your eyesight. Dedicated to saving sight and enhancing lives, they offer patients nine convenient locations, the comfort of the highest level of personalized care and expertise based on the latest cutting edge research, in a highly efficient way. Wagner Macula & Retina Center values patients’ trust and confidence and understands the challenges posed by diminishing eyesight. Find Wagner Macula & Retina Center on its Website, Facebook, and LinkedIn.

About Eyenuk, Inc.

Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. The EyeScreen™ Human+AI Diagnostic Service for diabetic retinopathy combines independent human specialist grading and artificial intelligence assessment to optimize detection of diabetic retinopathy. Eyenuk’s first autonomous AI product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of DR. The EyeArt System has CE marking in the EU and a Health Canada license. In the US, the EyeArt System is limited by federal law to investigational use. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease. Find Eyenuk online on its website, Twitter, Facebook, and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200504005201/en/